Stories
Experts Call For Affordable Blood Cancer Care And Genomic Testing In India
F
Firstpost•14-10-2026, 18:00
Experts Call For Affordable Blood Cancer Care And Genomic Testing In India
- •Experts at the HemeNext 2.0 conclave in Gurugram emphasized the need to make genomic testing and advanced therapies more accessible and affordable in India.
- •Discussions centered on precision diagnosis tools like next-generation sequencing and rapid genomic testing to guide targeted treatment choices.
- •Childhood blood disorders remain a pressing concern, with lymphoid leukaemia accounting for a significant percentage of cancers among children aged 0 to 14.
- •Specialists also examined practical barriers, safety requirements, and infrastructure costs associated with expanding access to CAR-T cell therapy and bone marrow transplantation.
- •The event brought together over 200 faculty members and 400 participants globally to discuss innovations, artificial intelligence in diagnostics, and long-term patient care.
Key Questions Answered
Experts at the HemeNext 2.0 conclave in Gurugram emphasized the urgent need to make genomic testing and advanced therapies like CAR-T cell treatment more accessible and affordable, while also strengthening early diagnosis and long-term patient care.
According to figures from the Indian Council of Medical Research–National Cancer Registry Programme cited at the event, lymphoid leukaemia accounts for approximately 29% of cancers among boys and 24% among girls aged 0–14 in India.
The paediatric programme focused on conditions such as leukaemia, inherited bone marrow failure, thalassaemia, sickle cell disease, and transplantation, while also examining survivorship, immune health, fertility preservation, and long-term treatment effects.
